aGVHD Clinical Trial
Official title:
Biomarker Identification for aGVHD After Allogeneic Stem Cell Transplantation: a Multiple Center Study
This is a prospective study in patients receiving allogeneic stem cell transplantation. The blood samples on Day-14, -7, 0 and every 7 days until D100 were collected together with clinical data. In the final analysis, cytokines and biomarkers analysis will be carried out and compared between patients in No aGVHD and grade II-IV aGVHD.
This is a prospective study, observation study in patients receiving allogeneic stem cell transplantation in 4 BMT centers in Shanghai. The blood samples (on Day-14, -7, 0 and every 7 days until D100) and clinical data will be collected. In the final analysis, a panel of cytokines and biomarkers analysis of serial blood samples will be carried out and compared between patients with no aGVHD and grade II-IV aGVHD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05531266 -
Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease
|
N/A | |
| Recruiting |
NCT02848105 -
Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD
|
Phase 2 | |
| Completed |
NCT03763318 -
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
|
Phase 1/Phase 2 | |
| Completed |
NCT02677181 -
Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
|
Phase 4 | |
| Completed |
NCT04397367 -
Low Dose Ruxolitinib in Combination With Methylprednisolone
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05214066 -
Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
|
Phase 2 | |
| Completed |
NCT04061876 -
First Line Therapy for High Risk Acute GVHD
|
Phase 2 | |
| Recruiting |
NCT05263999 -
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
|
Phase 3 |